

JC10 Rec'd PCT/PTO 2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

pplicant(s): Sanders et al.

Application No.: 10/537,280

Filed: 5/27/2005

Title: Binding Partners for the Thyrotropin

Receptor and Uses Thereof

Attorney Docket No.: URQU.P-016

Group Art Unit:

Examiner:

Assistant Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants request that the references listed on form PTO 1449, which is attached, be made of record in the US Patent and Trademark Office in the file relating to the abovecaptioned application. Copies of the listed non-US and non-patent references are enclosed.

This paper is submitted within three months of the filing date. Accordingly, no fee should be due. The Commissioner is authorized to charge any fees due in connection with this paper or credit any overpayment to Deposit Account No. 15-0610.

with sufficient postage as first class mail and addr Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on

JUL 1 8 2005

Name Sandra J. Lahmann

Signature S

Respectfully submitted,

Marina T. Larson, Ph.D.

Attorney/Agent for Applicant(s)

Reg. No. 32038

(970)4686600

Under	JUL 2 0 2005 6 Re Paperwork Reduced Act of 1995, no	o perso	ns are required to resp	U.S. Patent and Tradem	PTO/SB/08a (08-0 rebus use through 07/31/2006. OMB 0651-00: ark Office; U.S. DEPARTMENT OF COMMERC on unless it displays a valid OMB control numbe	
	RADE 49A/PTO			Complete if Known		
				Application Number	10/537,280	
	INFORMATION DISC	;LO	SURE	Filing Date		
	STATEMENT BY AP	PLI	CANT	First Named Inventor	Sanders et al.	
	(Use as many sheets as nec			Art Unit		
				Examiner Name		
Sheet	1	of	2	Attorney Docket Number	URQU.P-016	

U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
	No.1			Applicant of Cited Document				
	US-US 5,840,853A		11-24-1998	Segre et al.				
	<u>:</u>	US-			,			
		US-		·				
		US-						
		US-						
		US-						
		US-		·				
		US-						
	<u></u>	US-						
	<u></u>	US-						
		US-						
		US-						
		US-						
		US-						
		US-						
•		US-						
		US-						
		us-						
		US-						
		US-						

FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number*- Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	116			
		WO 03/018632	03-06-2003	Smith et al.					
		WO 91/09137	06-27-1991	Rapoport					
		WO 99/64865	12-16-1999	Sanders et al.					
		EP 1 078 986	02-28-2001	Hattori et al.					
<u> </u>		EP 0 719 858	07-03-1996	Matsuba et al.					
					,	_			

Examiner	Date	•
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of US PTO Patent Documents at www.upsto.gov or MPEP 901.04. Set For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitut	e for form 1449B/PTO	•		Complete if Known		
1815	ADMATION DIOC			Application Number	10/537,280	
INF	DRMATION DISC	LOS	URE	Filing Date		
STA	TEMENT BY AP	PLIC.	ANT	First Named Inventor	Sanders et at.	
				Art Unit		
	(Use as many sheets as nec	essary)		Examiner Name		
Sheet	2	of	2.	Attorney Docket Number	LIDOU D 016	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		CHAZENBALK ET AL., Thyroid-stimulating autoantibodies in Graves disease preferentially recognize the free A subunit, Journal of Clinical Investigation, 07/2002, Page(s) 209-217, Volume 110, Number 2	
		CUNDIFF ET AL., Studies using recombinant fragments of human TSH receptor reveal apparent diversity in the binding specificities, Journal of Clinical Endocrinology and Metabolism, 09/2001, Page(s) 4254-4260, Volume 86, Number 9	
	,	VAN DER HEIJDEN ET AL., Limitations of the semisynthetic library approach for obtaining human monoclonal autoantibodies to the thyrotropin receptor of Graves' disease, Clinical and Experimental Immunology, 1999, Page(s) 205-212, Volume 118	
		AKAMIZU ET AL., Characterization of Recombinant Monoclonal Antithyrotropin Receptor Antibodies (TSHRAbs) Derived from Lymphocytes of Patients with Graves' Disease, Endocrinology, 1999, Page(s) 1594-1601, Volume 140, Number 4	· ·
		SHEPHERD ET AL., Identification of an important thyrotrophin binding site on the human thyrotrophin receptor using monoclonal antibodies, Molecular and Cellular Endocrinology, 1999, Page(s) 197-206, Volume 149	
<u>-</u>	,	SANDERS ET AL., The Interaction of TSH Receptor Autoantibodies with I-Labelled TSH Receptor, The Journal of Clinical Endocrinology & Metabolism, 1999, Page(s) 3797-3802, Volume 84, Number 10	
		VALENTE ET AL., Monoclonal antibodies to the thyrotropin receptor: Stimulating and blocking antibodies derived from the lymphocytes of patients with Graves disease, Proc. Natl. Acad. Sci., 11/1982, Page(s) 6680-6684, Volume 79	
		MISRAHI ET AL., Human thyroid stimulatory hormone receptor (TSHR) mRNA, complete cds, NCBI Accession No: M32215, 1995	
*			
			-

Examiner		10	Date _	• •
Signature	<u> </u>	c	Considered	•

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.